Altris.AI: Funding, Investors & Team (Sep 2026)
Glaucoma and Age-related macular degeneration (AMD) are the main causes of irreversible blindness worldwide. Correct diagnosis at early stages of these diseases can significantly help ophthalmologists to prescribe appropriate treatment and thereby slow the progress of the disease and prevent significant vision loss. We are developing a software (AI platform), designed to improve the diagnostic process in ophthalmology by creating a deep learning trained algorithm for automated detection at early, asymptomatic stages of Glaucoma, Age-related macular degeneration (AMD) and other retinal diseases on OCT (optical coherence tomography) images by learning from a large dataset of clinical cases. Our goal is to develop state-of- the-art ophthalmology diagnosis real-time support platform with extension in many products such as mobile application, smart glasses, web platform and enterprise system. We build our products to help doctors leverage artificial intelligence, big data, augmented and mixed reality technologies in their daily activities. Our platform and products are bridging the gap in human-machine interaction in ophthalmology and retinal diagnostic.
Altris.AI has raised $1.0M across 1 funding round on record, the most recent an undisclosed round of $1.0M announced in Dec 2022.
That round is below the $4.1M median round size for Apps companies tracked on FundedIQ over the last two years.
Altris.AI Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Altris.AI Funding Rounds
Altris.AI Founders and Leadership Team
Contact details for the Altris.AI team: 1 of 1 has an email address on file.
Start 14-day free trial →Altris.AI Funding Compared to Other Apps Startups
Altris.AI's latest round of $1.0M is below the median round in Apps. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Altris.AI in Apps and Chicago
Companies Similar to Altris.AI
ChatBox is a simple, scalable solution for communicating with customers in their preferred medium —…
K Health is a digital primary care app that uses AI to provide personalized healthcare based on data…
The more intelligent no-code platform, Blaze, makes your company's operations better. We give you the…
Fly.io offers an Application Delivery Network (ADN) expected to assist site proprietors with getting…
WizCommerce is a platform utilizing artificial intelligence to assist B2B wholesalers, distributors, and…
Scaled Cognition offers a model that ensures customer interactions are based on verified answers that adhere…
Tickmark dba Taxfyle develops accounting-based applications for iOS and Android platforms as well as newly…
It is estimated that 45 million individuals are financial caregivers, meaning they are responsible for the…
Trovy is a fintech company that provides applications. analytics, and financial services.
Onyx Odds is a predictions company, specializing in sports predictions.
Valence AI provides real-time emotion AI that adds vocal emotion signals to customer intelligence. By…
Napkin Math is an AI food journal that gamifies nutrition tracking by offering customized guidance to achieve…
Altris.AI Funding FAQs
What does Altris.AI do?
Glaucoma and Age-related macular degeneration (AMD) are the main causes of irreversible blindness worldwide. Correct diagnosis at early stages of these diseases can significantly help ophthalmologists to prescribe appropriate treatment and thereby slow the progress of the disease and prevent significant vision loss. We are developing a software (AI platform), designed to improve the diagnostic process in ophthalmology by creating a deep learning trained algorithm for automated detection at early, asymptomatic stages of Glaucoma, Age-related macular degeneration (AMD) and other retinal diseases on OCT (optical coherence tomography) images by learning from a large dataset of clinical cases. Our goal is to develop state-of- the-art ophthalmology diagnosis real-time support platform with extension in many products such as mobile application, smart glasses, web platform and enterprise system. We build our products to help doctors leverage artificial intelligence, big data, augmented and mixed reality technologies in their daily activities. Our platform and products are bridging the gap in human-machine interaction in ophthalmology and retinal diagnostic.
How much funding has Altris.AI raised?
Altris.AI has raised $1.0M across 1 round on record. The most recent is an undisclosed round of $1.0M announced in Dec 2022.
When did Altris.AI last raise funding?
Altris.AI's most recent funding round on record is an undisclosed round of $1.0M, announced in Dec 2022.
Who founded Altris.AI?
FundedIQ lists Maria Znamenska (Founder) at Altris.AI.
Where is Altris.AI headquartered?
Altris.AI is based in Chicago, Illinois, United States.
How many employees does Altris.AI have?
Altris.AI is in the 11-50 employee band.
How does Altris.AI's funding compare to other Apps startups?
Altris.AI's latest round of $1.0M is below the $4.1M median round size for Apps companies on FundedIQ across 2,426 tracked companies over the last two years.
About FundedIQ's Altris.AI Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Altris.AI is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.